MAIN RESULTS:
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease
Circulation. 2022;146:1109–1119.
MAIN RESULTS PRESENTATIONS
FOURIER Open Label Extension Primary Results (O’Donoghue, ESC 2022)
PRESENTATIONS
Association Between Achieved LDL-Cholesterol and Long-term Cardiovascular and Safety Outcomes – An Analysis of the FOURIER and FOURIER-OLE Studies (Gaba, AHA 2022)
Reduction in Total CV Events with the PCSK9 Inhibitor Evolocumab in Patients with Cardiovascular Disease in the Combined FOURIER and FOURIER OLE Studies (Murphy, ACC 2023)
Long-term PCSK9 Inhibition with Evolocumab and Aortic Stenosis Events (Gaba, TCT 2023)
Association Between Achieved LDL-Cholesterol Levels and Long-term Cardiovascular and Safety Outcomes-An Analysis of FOURIER-OLE (Gaba, AHA 2023)
Long-Term Efficacy of Evolocumab in Patients with and without Multi-Vessel Disease (McClintick, AHA 2023)
Long-Term Neurocognitive Safety of LDL-C Lowering with Evolocumab-Open-Label Extension Data from FOURIER (Zimerman, AHA 2023)
Long-Term Evolocumab in Elderly Patients With Established Atherosclerotic Cardiovascular Disease – An Analysis from FOURIER and FOURIER-OLE (Al Said, ACC 2024)
Early Initiation of Evolocumab and Arterial Aneurysm Events in FOURIER & FOURIER-OLE (Gaba, AHA 2024)
Evolocumab and complex coronary revascularization during 8-year follow-up-Analysis from the FOURIER and FOURIER OLE trials (Haller, ACC 2025)
Efficacy and Safety of Very Low Achieved LDL-Cholesterol in Patients with Prior Ischemic Stroke (Monguillon, AHA 2025)